Bank of New York Mellon
OKUR

Bank of New York Mellon’s OnKure Therapeutics OKUR Stock Holding History

Bank of New York Mellon’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Buy
+72,215
New +$310K ﹤0.01% 3954
2024
Q2 		– Sell
-3,423
Closed -$56.8K – 4280
2024
Q1 		$56.8K Sell
3,423
-977
-22% -$16.1K ﹤0.01% 4075
2023
Q4 		$70.4K Buy
4,400
+804
+22% +$50.1K ﹤0.01% 4134
2023
Q3 		$274K Buy
3,596
+416
+13% +$28.3K ﹤0.01% 3847
2023
Q2 		$209K Buy
+3,180
New +$256K ﹤0.01% 3964
2022
Q2 		– Sell
-1,344
Closed -$39K – 4717
2022
Q1 		$39K Sell
1,344
-12
-0.9% -$671 ﹤0.01% 4558
2021
Q4 		$116K Buy
1,356
+74
+6% +$5.43K ﹤0.01% 4383
2021
Q3 		$95K Sell
1,282
-202
-14% -$17.1K ﹤0.01% 4342
2021
Q2 		$138K Buy
+1,484
New +$166K ﹤0.01% 4165

Other funds holding OKUR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Bank of New York Mellon's OKUR Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in OnKure Therapeutics (OKUR) in Q2 2026: 72,215 shares worth $329K. The stake represents ﹤0.01% of the portfolio and ranks #3954 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in OKUR as recently as Q1 2024.

Bank of New York Mellon first reported a position in OKUR in Q2 2021 and has held it in 9 quarters since. 20 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Bank of New York Mellon held 72,215 shares of OnKure Therapeutics worth $329K as of Q2 2026.
  • OnKure Therapeutics was a new Bank of New York Mellon position in Q2 2026.
  • OnKure Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3954 holding.
  • Bank of New York Mellon first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • 20 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.